BACKGROUND: No medical therapy has been proven to prevent the progression of aortic dilatation in bicuspid aortic valve (BAV) disease, and prophylactic aortic surgery remains the mainstay of treatment. HYPOTHESIS: Among patients with BAV disease who are referred for surgery, preoperative statin use is associated with decreased odds of ascending aortic dilatation. METHODS: We reviewed all BAV patients who underwent aortic valve and/or aortic surgery at our center between April 2004 and December 2013. Aortic diameter (AD), defined as the maximum ascending aortic dimension, was determined by magnetic resonance imaging, computed tomography, or echocardiography. Patients were divided into 2 groups: maximal AD <4.5 cm or ≥4.5 cm. The association between preoperative statin use and aortic dilatation was assessed using multivariable logistic regression modeling. RESULTS: Of 680 consecutive patients, 405 (60%) had AD <4.5 cm (mean age, 60 ± 14 years; 45% on statins), whereas 275 (40%) had AD ≥4.5 cm (mean age, 54 ± 13 years; 35% on statins) at the time of surgery. After adjusting for age, body surface area, sex, hypertension, aortic stenosis, severity of aortic regurgitation, and use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and β-blockers, patients with AD ≥4.5 cm had 0.66× lower odds (95% confidence interval: 0.45-0.96) of being on preoperative statins compared with those with AD <4.5 cm (P = 0.029). CONCLUSIONS: In a retrospective study of BAV patients referred for surgery, preoperative statin use was associated with lower odds of clinically significant ascending aortic dilatation.
BACKGROUND: No medical therapy has been proven to prevent the progression of aortic dilatation in bicuspid aortic valve (BAV) disease, and prophylactic aortic surgery remains the mainstay of treatment. HYPOTHESIS: Among patients with BAV disease who are referred for surgery, preoperative statin use is associated with decreased odds of ascending aortic dilatation. METHODS: We reviewed all BAV patients who underwent aortic valve and/or aortic surgery at our center between April 2004 and December 2013. Aortic diameter (AD), defined as the maximum ascending aortic dimension, was determined by magnetic resonance imaging, computed tomography, or echocardiography. Patients were divided into 2 groups: maximal AD <4.5 cm or ≥4.5 cm. The association between preoperative statin use and aortic dilatation was assessed using multivariable logistic regression modeling. RESULTS: Of 680 consecutive patients, 405 (60%) had AD <4.5 cm (mean age, 60 ± 14 years; 45% on statins), whereas 275 (40%) had AD ≥4.5 cm (mean age, 54 ± 13 years; 35% on statins) at the time of surgery. After adjusting for age, body surface area, sex, hypertension, aortic stenosis, severity of aortic regurgitation, and use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and β-blockers, patients with AD ≥4.5 cm had 0.66× lower odds (95% confidence interval: 0.45-0.96) of being on preoperative statins compared with those with AD <4.5 cm (P = 0.029). CONCLUSIONS: In a retrospective study of BAV patients referred for surgery, preoperative statin use was associated with lower odds of clinically significant ascending aortic dilatation.
Authors: M L McDonald; N G Smedira; E H Blackstone; R A Grimm; B W Lytle; D M Cosgrove Journal: J Thorac Cardiovasc Surg Date: 2000-06 Impact factor: 5.209
Authors: Paul W M Fedak; Subodh Verma; Tirone E David; Richard L Leask; Richard D Weisel; Jagdish Butany Journal: Circulation Date: 2002-08-20 Impact factor: 29.690
Authors: Gian M Novaro; Irving Y Tiong; Gregory L Pearce; Richard A Grimm; Nicholas Smedira; Brian P Griffin Journal: Am J Cardiol Date: 2003-07-01 Impact factor: 2.778
Authors: Paul W M Fedak; Mauro P L de Sa; Subodh Verma; Nafiseh Nili; Pedram Kazemian; Jagdish Butany; Bradley H Strauss; Richard D Weisel; Tirone E David Journal: J Thorac Cardiovasc Surg Date: 2003-09 Impact factor: 5.209
Authors: Catherine Tcheandjieu; Ke Xiao; Helio Tejeda; Julie A Lynch; Sanni Ruotsalainen; Tiffany Bellomo; Madhuri Palnati; Renae Judy; Derek Klarin; Rachel L Kember; Shefali Verma; Aarno Palotie; Mark Daly; Marylyn Ritchie; Daniel J Rader; Manuel A Rivas; Themistocles Assimes; Philip Tsao; Scott Damrauer; James R Priest Journal: Nat Genet Date: 2022-05-30 Impact factor: 41.307
Authors: Jacob Gutierrez; Brett A Davis; Kimberly A Nevonen; Samantha Ward; Lucia Carbone; Cheryl L Maslen Journal: Front Genet Date: 2022-05-31 Impact factor: 4.772
Authors: Erin E Crawford; Patrick M McCarthy; S Chris Malaisrie; Christopher K Mehta; Jyothy J Puthumana; Joshua D Robinson; Michael Markl; Robert O Bonow; Paul W M Fedak Journal: Ann Cardiothorac Surg Date: 2022-07